iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome

Advances in Nanotechnology-Based Drug Delivery in Targeting PI3K Signaling in Respiratory Diseases

“…Oxidative stress and cytokine storm were also remarkably suppressed by iRGD-NIMLip in contrast to free nimbolide. Thus, these findings suggest that advanced drug delivery system can be employed as novel therapeutics targeting chronic lung inflammation and other pathological consequences associated with COVID-19 and other CRDs [20].…”

“…Taken together, these findings suggest that liposomal nanovehicles enable a targeted approach in enhancing phagocytosis and ameliorate chronic inflammatory response in cystic fibrosis patients [19]. Furthermore, a recent study by Pooladanda et al engineered iRGD peptide-conjugated liposomes loaded with nimbolide (iRGD-NIMLip), an anti-inflammatory phytomedicine, in treating acute respiratory distress syndrome, which shares many of the clinical manifestations as those associated with the recent outbreak of the COVID-19 [20]. It was reported that iRGD-NIMLip attenuated lipopolysaccharide-induced expressions of inflammatory genes via the PI3K/Akt/mTOR signaling pathway.…”

Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal

“…In this connection, poly­(lactic- co -glycolic acid) (PLGA) nanoparticles of nimbolide that exhibit sustained release and enhanced cytotoxicity in breast and pancreatic cancer cell lines relative to free nimbolide raise hope for targeted delivery by conjugation with polyethylene glycol or receptor-binding ligands . Conjugation of nimbolide liposomes conjugated with iRGD peptide (iRGD-NIMLip) was found to be a promising novel drug delivery system to target lung inflammation based on the significant inhibition of oxidative stress and cytokine storm associated with acute respiratory distress syndrome and COVID-19 . Further studies on targeted delivery will open up new possibilities for therapeutic intervention.…”

Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19

“…Following the risk analysis, the succeeding eight variables were classied as high-risk parts inuencing liposome; drug encapsulation and particle size: lipid concentration, drug concentration, cholesterol concentration, buffer concentration, hydration time, sonication period, number of freeze-thaw cycles, and extrusion pressure. 130 Pooladanda et al 131 synthesized iRGD conjugated nimbolide liposomes (iRGD-NIMLip) for treating COVID-19 related diseases and studied their effect in vivo (male C57BL/6 mice (5-6 weeks old)). The animal experiment assumed that iRGDconjugated nimbolide liposomes treatment signicantly repressed oxidative stress and cytokine storm associated with free-drug and showed higher activity than dexamethasone (DEX).…”

“…Pooladanda et al 131 synthesized iRGD conjugated nimbolide liposomes (iRGD-NIMLip) for treating COVID-19 related diseases and studied their effect in vivo (male C57BL/6 mice (5–6 weeks old)). The animal experiment assumed that iRGD-conjugated nimbolide liposomes treatment significantly repressed oxidative stress and cytokine storm associated with free-drug and showed higher activity than dexamethasone (DEX).…”